… Scientific Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, … to provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … new strategy, including further building out the Company’s Axiomer RNA-editing technology as a value-generating …
… X: Late-breaking clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be … PhD, Sr. scientist computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: … Western world have LCA10 because of this mutation. About Axiomer ® Technology Platform ProQR is pioneering a …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… based on novel RNA editing technologies including our Axiomer ® technology." Dr. Yu is a professor of biochemistry … that do not currently have treatment options." About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ … through intravitreal injections in the eye. About Axiomer ® Technology Platform ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St